|
PRESS RELEASE
New Very High Fluorescence Library of Peptide Substrates for Protease HTS
Paris, April 5th, 2006, NEW VERY EFFICIENT FLUORESCENT PROBES FOR HTS: Pharmaleads, a French biotech specialised in the custom design of substrates and inhibitors for all types of proteases announces the availability of its new FLUOFAST PROTEASE technology for the rapid identification of a fluorogenic substrate for a given PROTEASE from a large proprietary substrate library. The patented process of FLUOFAST relies on the fluorogenic activity of Pyrenylalanine(Pya) separated from a quencher (Nop) by 0 to 5 amino-acids. This Pya-Nop couple was introduced by Pharmaleads in a very small water soluble peptide. The resulting peptide substrates are organised in a library that is used for rapid screening that leads to the identification of a substrate for a known protease.
A technical description is available on : http://www.pharmaleads.com/en/page16.xml
FLUOFAST PROTEASE represents a significant improvement for HTS managers and senior scientists:
 the very strong fluorescence provided by Pya means a high sensitivity of the identified substrate,
the identified substrate is very easy to handle in further analytical and HTS processes.
Moreover Pharmaleads can bring its expertise to the design of a substrate for a given protease which needs to meet specific requirements such as a high affinity or similarity to the physiological substrate (see http://www.pharmaleads.com/en/cataloglist.xml for the full technical description of some of the substrates and inhibitors developed by Pharmaleads).
Pharmaleads (http://www.pharmaleads.com/) is a biotech company, founded in 2000, specialised in the design of substrates and inhibitors for the research divisions of pharmaceutical companies. The business development model of Pharmaleads is based on technology licence agreements and product sales. Pharmaleads has recently produced very innovative results for botulinum toxins (BoNT/A, BoNT/B), ECE, NEP, APA, APN, ACE, … and has developed efficient, selective, dual and triple inhibitors for different metallopeptidases. Pharmaleads also conducts a promising line of activity on pain relief and analgesia.
Contact: Tanja Ouimet, Head of Biochemistry dpt
Tanja.ouimet@pharmaleads.com
Fax: +33 1 44 06 60 99
|
